Fri, Apr 18, 2014, 1:11 PM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Baron Partners Retail Message Board

jr330762 8 posts  |  Last Activity: Apr 5, 2014 8:59 AM Member since: Mar 16, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    ...beware of Dr John:

    by drrjohn Feb 23, 2014 11:24 AM
    jr330762 jr330762 Apr 5, 2014 8:59 AM Flag

    so what is a screaming buy?

  • Reply to

    Good moves. I like the company's prospects.

    by smudge1260 Feb 13, 2014 4:11 PM
    jr330762 jr330762 Mar 18, 2014 2:52 PM Flag

    great success with CHTP? Are you kidding? His insensitivity to FDA politics cost him his job at CHTP and caused a long delay to getting Northera approved. In fact, the only reason Northera was not approved sooner is this CEO. As soon as CHTP fired him, the FDA did a complete 360 in what they required of CHTP for approval, and then approved their drug. FDA went from requiring long term studies requiring durability of effect in the CRL issued to Pedder to nevermind, no durability of effect needed, resubmit your NDA post Pedder firing. Nothing changed in between other than the CEO.....the CEO that kept throwing mud on FDA's face for not requiring post approval studies of Shire for midodrine to the point where FDA threatened to pull midodrine off market....only to be met with bad press since 50,000 people use midodrine and there is/was no alternative at the time.

  • Reply to

    The CHTP story soon- From Orphan to Blockbuster

    by m_waters49 Mar 14, 2014 3:52 PM
    jr330762 jr330762 Mar 15, 2014 12:50 PM Flag

    Chelsea Therapeutics Receives Notice of Allowance of Key U.S. Patent for Novel, Controlled Release Formulation of Northera(TM)

    December 15, 2011

    Patent Offers Protection of Once-A-Day Formulation Until at Least 2026

    CHARLOTTE, N.C., Dec. 15, 2011 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a notice of allowance from the U.S. Patent & Trademark Office (USPTO) for its patent application “Threo-DOPS Controlled Release Formulation,” U.S. Patent Application Number 11/698,974. Upon issuance, the patent will expire no earlier than 2026.

    The newly allowed claims relate to certain oral, controlled release formulations of Northera™ (droxidopa) that include an extended release component and an immediate release component. The patent will establish protection for a once-a-day Northera beyond the seven-year marketing exclusivity afforded by its orphan designation in the U.S., enabling Chelsea to pursue the therapeutic development of Northera in indications expected to benefit from a controlled release formulation.

    “This patent allowance notice from the USPTO provides key support for the intellectual property protection we are building for Northera,” said Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. “This latest patent could provide significant growth opportunities for Chelsea, as we investigate additional, potential therapeutic applications of Northera which is currently under review at the FDA for the treatment of symptomatic, neurogenic orthostatic hypotension and has a PDUFA date of March 28, 2012.”

    This notice of allowance marks the second major milestone for the Company’s intellectual property pursuits this year. In August 2011, the United States Patent and Trademark Office issued U.S. Patent No. 8,008,285 entitled “Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia.” The claims of the patent are related to methods of reducing pain associated with fibromyalgia by administering droxi

  • Reply to

    The CHTP story soon- From Orphan to Blockbuster

    by m_waters49 Mar 14, 2014 3:52 PM
    jr330762 jr330762 Mar 15, 2014 12:48 PM Flag

    they already have patent on extended release version of droxidopa.

  • Reply to

    ...beware of Dr John:

    by drrjohn Feb 23, 2014 11:24 AM
    jr330762 jr330762 Feb 26, 2014 3:52 PM Flag

    in the same boat as closertofreee as far as my feelings towards Dr John's commentary. Awesome stuff and I only wish I could get real time Doc John buys so I can get in when you get in. I shy away from the pics that are up 20% a few days following your mention of them only to see them go up another 100% in the following months. Surprised to see mdxg as one of your favorites. It's hard to buy a stock at $1 and then buy more at $7......I don't think I can do it but will try. Been thinking of selling MRIC. Was on a camping trip and there was a neurosurgeon in our group. I asked him about using mri in the OR and he said it's been around for years and that he even studied under a guy who invented a way to transport them between one location in a hospital to OR and use them during surgery. He never heard of MRIC.

  • Reply to

    what a real brain surgeon knows of this technology

    by jr330762 Feb 22, 2014 7:34 AM
    jr330762 jr330762 Feb 22, 2014 7:34 AM Flag

    obviously meant to type MRIC not uric….oops

  • asked a friend of friend who happens to be brain surgeon about the use of MRI in the OR. Said he never heard of this company, but that using MRI in the OR has been around for a while. Said that a guy he knew built a machine that picks up and moves an MRI machine and that is how it is done. I own a few shares in uric but am considering vacating…..

  • Nobody talking about this now, but it should be mentioned. Ready to start designing ph 3 studies in these indications….

BPTRX
34.59+0.09(+0.26%)Apr 17 6:24 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT